{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-030064","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2024-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.711292+00:00","generated_at":"2026-06-05T05:32:03.336290+00:00","sec_items":["1.01","2.03","3.02","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Jaguar Health extinguishes $10M royalty with Streeterville via Series J Preferred; exchanges PIPE warrants for common","bullets":["Exchanged $10M March 2021 Royalty Interest with Streeterville for 179.3822 shares of Series J Preferred Stock.","Series J Preferred has 0% dividend first 2 years, then 10%/15%; non-convertible but exchangeable by company at Minimum Price.","PIPE Warrants to purchase up to 7,535,000 shares exchanged for 18,837,500 common shares at 1-for-2.5 ratio.","PIPE Exchange Shares subject to 12-month lock-up; other equity of PIPE investors locked 6 months.","Series J Preferred includes covenants restricting equity issuances >$15M without holder consent and limits on asset dispositions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-030064","json":"https://secwatch.observer/filing/0001104659-24-030064.json","markdown":"https://secwatch.observer/filing/0001104659-24-030064.md","text":"https://secwatch.observer/filing/0001104659-24-030064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000110465924030064/0001104659-24-030064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000110465924030064/tm247635d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T05:32:03.336290+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b7c37162707bef6aa8030cddcaac3bd76d1f8f0","claim":"Jaguar Health, Inc.: Filed Certificate of Designation for Series J Preferred Stock with Delaware Secretary of State on March 1, 2024, effective upon filing, authorizing 200 shares of Series J Preferred Stock (effective 2024-03-01).","evidence_excerpt":"Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Series J Certificate of Designation As disclosed under Items 1.01 and 3.02 above, in connection with the CVP Exchange Transaction, the Company agreed to issue shares of Series J Preferred Stock to Streeterville. The preferences, rights, limitations and other matters relating to the Series J Preferred Stock are set forth in the Certificate of Designation, which the Company filed with the Secretary of State of the State of Delaware on March 1, 2024. The Certificate of Designation became effective with the Secretary of State of the State of Delaware upon filing.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000110465924030064/0001104659-24-030064-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-03-01"}],"fact_type":"governance_change"},{"claim_id":"5a9da1f798e1b9c936a3d4802e7dd42b74828194","claim":"Jaguar Health, Inc. entered into PIPE Warrant Exchange Agreements with the PIPE Investors (effective 2024-02-27).","evidence_excerpt":"On February 27, 2024, each of the PIPE Investors entered into an exchange agreement with the Company (each, a “PIPE Warrant Exchange Agreement” and collectively, the “PIPE Warrant Exchange Agreements”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000110465924030064/0001104659-24-030064-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the PIPE Investors"},{"label":"Effective","value":"2024-02-27"}],"fact_type":"material_agreement"},{"claim_id":"6bd4d92760f869099bb42fea00f04904bb9e12df","claim":"Jaguar Health, Inc. entered into Streeterville Exchange Agreement with Streeterville Capital, LLC (effective 2024-03-01).","evidence_excerpt":"On March 1, 2024, the Company entered into a privately negotiated exchange agreement with Streeterville (the “Streeterville Exchange Agreement”), pursuant to which the Company issued an aggregate of 179.3822 shares of Series J Preferred Stock to Streeterville at an effective exchange price per share equal to the market price (defined as the Minimum Price under Nasdaq Listing Rule 5635(d)) as of the date of the Streeterville Exchange Agreement, in exchange for the surrender of the March 2021 Royalty Interest by Streeterville (the “CVP Exchange Transaction”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000110465924030064/0001104659-24-030064-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Effective","value":"2024-03-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}